Bill
S 1583
Restricts gifts and marketing by pharma/medical device makers to health workers and facilities, requires annual disclosures to DPH, and bans most direct incentives.
Status: Filed January 16, 2025 (Senate Docket No. 1435). Introduced/acted on in 2025; referred to committee(s) (see “Procedural status” below). Presented by Sen. Mark C. Montigny (Second Bristol and Plymouth).
Note on metadata: the bill text is a Massachusetts bill amending Chapter 111N (public health / industry marketing). Some provided metadata (title line, sponsor list, and procedural entries) appear inconsistent or from other jurisdictions; this summary focuses on the bill text as supplied.
Purpose
- To restrict marketing practices by pharmaceutical and medical device manufacturers and their agents, prohibit gifts to health care practitioners and related recipients, and increase transparency through mandatory disclosures to the Massachusetts Department of Public Health (DPH).
Key provisions (from provided text)
- Replaces sections 1–7 of Chapter 111N with new definitions and requirements.
- Definitions: establishes statutory meanings for terms including “department” (DPH), “education program” (medical school, teaching hospital, teaching health center), “gift,” “health care practitioner,” “medical device,” “pharmaceutical or medical device manufacturer agent,” and “pharmaceutical or medical device manufacturing company.”
- “Gift” is broadly defined to include payments, entertainment, meals, travel, honoraria, subscriptions, advances, services, or anything of value unless equal-value consideration exists under an explicit contract with non‑marketing deliverables restricted to medical/scientific issues.
- Exclusions from “gift” include inheritance, certain close-relative gifts, and prescription drugs provided solely for patient use.
- Ban on gifts: Section 2 prohibits a pharmaceutical or medical device manufacturer agent from knowingly offering or giving any gift of any value to:
- health care practitioners, their immediate family, their employees/agents;
- health care facilities and their employees/agents;
- education programs and their employees/agents.
- Exceptions: distribution/receipt of peer‑reviewed academic, scientific or clinical information and purchase of advertising in peer‑reviewed journals are permitted.
- Annual disclosure requirement (Section 3, partial text): Requires each pharmaceutical or medical device manufacturing company to disclose to the DPH by July 1 each year the value, nature, purpose, and recipient of any fee, payment, subsidy, or other economic benefit (not prohibited by the gift ban) provided directly or through agents to physicians, hospitals, nursing homes, pharmacists, health benefit plan administrators, education programs, etc. (Text is truncated; full reporting mechanics, timelines, and enforcement provisions are not present in the excerpt.)
Who is affected
- Pharmaceutical and medical device manufacturing companies and their marketing agents active in Massachusetts.
- Physicians and other licensed health care practitioners who prescribe drugs or use devices, their immediate family members, employees and agents.
- Hospitals, nursing homes, teaching institutions/education programs, pharmacists, and health benefit plan administrators.
- Potentially patients and the public through altered industry‑clinician interactions and increased public transparency (depending on public reporting rules).
Potential impacts
- Reduces direct financial and in‑kind marketing incentives from manufacturers to clinicians and institutions.
- Increases transparency about permitted payments or benefits via mandatory annual disclosures to the DPH.
- May raise compliance costs for manufacturers and require new reporting systems.
- Could change industry engagement with clinicians, impacting continuing medical education, speaker programs, and promotional activities—while preserving dissemination of peer‑reviewed scientific information.
Procedural status and timeline (as provided)
- Filed: 01/16/2025 (Senate Docket No. 1435).
- Introduced/Read twice: 05/01/2025 (various entries provided).
- Committee referrals/hearing: multiple committee referrals noted (Public Health; Investigations and Government Operations; Health Care Financing); hearing scheduled 06/11/2025 in A‑1 (01:00–05:00 PM). Reported favorably by committee and referred to Health Care Financing on 09/04/2025.
- Note: the procedural log supplied contains inconsistent dates and overlapping entries; confirm current status with official Massachusetts legislative sources for up‑to‑date action history.
Limitations
- The provided bill text is truncated (Section 3 and subsequent sections cut off). Details on enforcement, penalties, public disclosure format, exemptions, compliance timelines, and amendments to existing enforcement mechanisms are not available in the excerpt and would be important to evaluate full effect.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
